Liminatus Pharma, Inc.
SEC CIK 1971387 · LIMN · last insider filing 2025-08-15
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Lemons II Philip Wayne | Director | filed 2025 - 2025 |
| Baek Richard Jaihwan | Director | filed 2025 - 2025 |
| Kim Chris | Director · Chief Executive Officer | filed 2025 - 2025 |
| Lee Eun Sook | Director | filed 2025 - 2025 |
| Fernandez Nicholas | Director | filed 2025 - 2025 |
| Baek Ji Yeon | Director | filed 2025 - 2025 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Lee Sang-Jin | Head of Research & Development | filed 2025 - 2025 |
| Dam Scott | Chief Financial Officer | filed 2025 - 2025 |
| Choi Beom Kyu | Chief Technology Officer | filed 2025 - 2025 |
| Yoo Byong Chul | Chief Science Officer | filed 2025 - 2025 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.